TFOS DEWS III: New Framework Shifts Dry Eye Diagnosis to Driver-Based Approach

Dry eye disease has long been a puzzle that clinicians tried to solve by sorting patients into neat categories: evaporative or aqueous-deficient. But the framework that governed this thinking—published nearly a decade ago—was beginning to feel too rigid for the complexity of what doctors were actually seeing in their exam rooms. In 2025, the Tear Film & Ocular Surface Society released an updated report, TFOS DEWS III, that fundamentally reorients how eye care professionals approach diagnosis and treatment. Rather than forcing patients into predetermined boxes, the new guidance asks clinicians to identify the specific drivers of disease in each individual and build treatment around those drivers.

The shift is more than semantic. Dry eye disease remains defined as a multifactorial condition marked by loss of homeostasis in the tear film and ocular surface—a disruption of the eye's natural balance. But TFOS DEWS III places far greater emphasis on understanding how tear film instability, hyperosmolarity, inflammation, and neurosensory abnormalities interact in each patient, rather than assigning everyone to a broad category. This distinction matters because it changes what clinicians do in practice. Instead of a checklist applied uniformly to every patient, the new framework calls for a structured but flexible workflow tailored to individual presentation.

The diagnostic process begins with conversation. A clinician should ask whether a patient experiences pain or mere discomfort—pain without trauma or infection might signal corneal neuropathy rather than dry eye. Questions about facial flushing, mouth dryness, or enlarged salivary glands can point toward rosacea or immune-mediated conditions like Sjögren's disease. The timing and character of symptoms matter: sudden onset warrants investigation for infection or trauma, while chronic symptoms fit the dry eye pattern. Whether vision improves with blinking, whether symptoms are worse in one eye or both, whether there is itching or discharge—each answer narrows the diagnostic field. This careful history-taking is the foundation. It distinguishes dry eye disease from other conditions that mimic it.

Once history is established, symptom assessment provides a standardized measure. The OSDI-6 questionnaire, freely available in multiple languages, quantifies what patients report. A score of four or higher suggests dry eye; scores between four and eight indicate mild-to-moderate disease, while nine to twenty-four signals severity. This tool brings consistency to what can otherwise be a subjective experience. Patients with dry eye often report symptoms that fluctuate throughout the day, worsening on waking or toward evening, particularly for contact lens wearers. A validated questionnaire captures this variation in a way that allows clinicians to track change over time.

Clinical examination then confirms what the patient reports. Testing should proceed from least invasive to most invasive, focusing on three key areas: tear film instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities. Diagnosis requires both a positive symptom score and at least one clinical sign of disrupted homeostasis. Clinicians should assess meibomian gland function, lid structure, and blink rate and completeness—all influence tear film stability. Lid margin staining from lid wiper epitheliopathy can appear earlier than corneal staining as disease progresses. The framework explicitly warns against exhaustive testing. Instead, clinicians should focus on core tests and clinical evaluation, ruling out other diagnoses while identifying the dominant disease drivers in each patient.

Once dry eye disease is confirmed, the work shifts to determining what is driving it. Studies show that roughly two-thirds of dry eye cases are evaporative—arising from eyelid or ocular surface issues—yet the new framework moves beyond simply labeling cases this way. Instead, clinicians identify the specific etiological drivers in each patient: tear film deficiencies, eyelid anomalies, ocular surface abnormalities, systemic health factors. This granular understanding allows for targeted intervention. A patient with meibomian gland dysfunction needs different management than one with reduced tear production, even if both present with dry eye symptoms. The TFOS DEWS III report links test results directly to specific interventions, creating a pathway from diagnosis to treatment.

The framework also acknowledges lifestyle factors that contribute to disease: screen time, reduced blink rate, poor sleep, cosmetics, environmental exposures. Recommendations include screen breaks, optimizing blink quality, improving sleep, adjusting indoor humidity. These modifications are not peripheral to treatment—they are central to it. Patient education and engagement emerge as vital. When patients understand what is driving their symptoms and how their own behavior influences the condition, they become active participants in their care rather than passive recipients of treatment.

Long-term management requires consistent monitoring over time. Electronic medical record platforms and registries have made this feasible in ways that paper records never could. The Save Sight Dry Eye Registry, for example, enables clinicians to track symptoms and assessments, capture patient-reported outcomes via the OSDI questionnaire, and visualize the patient journey over months and years. Clinicians using such registries can earn continuing professional development credits while gaining the ability to benchmark their practice against peers. Real-world data strengthens clinical decision-making and patient education alike. The framework, in essence, calls for a return to careful observation and individualized thinking—but armed with modern tools to make that thinking systematic, trackable, and continuously refined.